ACSL4 and neoplasm: Upregulation of ACSL4 inhibits the retinoic acid-inducible gene I-mitochondrial antiviral-signaling protein (RIG-I-MAVS) pathway, leading to decreased interferon-beta (IFN-β) production, impaired T-cell chemotaxis, and ultimately promoting tumor immune escape and progression [131].